Discriminative Stimulus Effects of Psychostimulants and Hallucinogens in S()-3,4-Methylene-dioxy-meth amphetamine (MDMA) and R()-MDMA Trained Mice K. S. Murnane, N. Murai, L. L. Howell, and W. E. Fantegrossi THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, Vol. 331, No. 2 Copyright © 2009 by The American Society for Pharmacology and Experimental Therapeutics 156174/3525473 JPET 331:717–723, 2009 Preliminary findings from these experiments were previously presented as follows : Murnane K.S., 2008 Expérimentalement Biology Meeting; San Diego, CA. doi:10.1124/jpet.109.156174. ABSTRACT 3,4-Methylenedioxymethamphetamine (MDMA) is a substituted phenethylamine more commonly known as the drug of abuse “ecstasy.” The acute and persistent neurochemical effects of MDMA in the mice are distinct from those in [...]
Lire la suiteChanges in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5- HT2A receptor Katrin H. Preller, Joshua B. Burt, Jie Lisa Ji, Charles Schleifer, Brendan D. Adkinson, Philipp Stampfli, Erich Seifritz, Grega Repovs, John H. Krystal, John D. Murray, Franz X. Vollenweider, Alan Anticevic eLife, 2018, 7, e35082. DOI: https://doi.org/10.7554/eLife.35082.001 Abstract Background : Lysergic acid diethylamide (LSD) has agonist activity at various serotonin (5-HT) and dopamine receptors. Despite the therapeutic and scientific interest in LSD, specific receptor contributions to its neurobiological effects remain unknown. Methods : We therefore conducted a double-blind, randomized, counterbalanced, cross-over study (ClinicalTrials.gov, NCT02451072) during which [...]
Lire la suiteModern History of Medical Cannabis : From Widespread Use to Prohibitionism and Back Simona Pisanti and Maurizio Bifulco Trends in Pharmacological Sciences, Cell Press, 2017, 38, 3, 195-198. doi: 10.1016/j.tips.2016.12.002. Over the history of pharmacology there are numerous examples of drugs being widely distributed, almost ‘trendy’, prescribed by physicians in a certain period as a sort of panacea, and then neglected, forgotten, or even forbidden as they become considered dangerous in the light of clinical observations. One of these drugs is Cannabis, which was very popular in the 19th century until disappearing from the official Pharmacopoeia at the beginning of the 20th century and [...]
Lire la suiteIntroduction to Recent Advances in Cannabinoid Research Robert B. Laprairie and Will Costain © 2016 The Author(s). Licensee InTechOpen. This chapter is distributed under the terms of the Creative Commons; Attribution License (http://creativecommons.org/licenses/by/3.0), Abstract On October 17, 2018, Canada became the first G20 nation to legalize the use of Cannabis sativa for both medicinal and recreational purposes. This change in legislation and end of prohibition are indicative of a larger global movement to understand Cannabis—and the bioactive chemicals present within Cannabis known as the cannabinoids—for its potential biomedical uses, harms, and economic values. Currently, interest in Cannabis and cannabinoid research is surging as the many [...]
Lire la suiteCannabis thérapeutique : au seuil de l’expérimentation Interview du Pr Nicolas Authier, chef du service de pharmacologie médicale, CHU de Clermont-Ferrand, président du Comité scientifique spécialisé temporaire (CSST) sur le cannabis thérapeutique JIM.fr, 16 juin 2019 cliquer sur "regardez sur Vimeo" ou : https://www.jim.fr/medecin/videos/e-docs/cannabis_therapeutique_au_seuil_de_lexperimentation_178085/document_jim_tube.phtml Chapitres Quelle différence existe-t-il entre cannabis thérapeutique et cannabis récréatif ? - 00:05 Quelle est la situation actuelle du cannabis thérapeutique en France ? - 00:54 Où en sont les travaux du CSST que vous présidez ? - 03:10 Quelles seront les indications du cannabis thérapeutiques pendant l’expérimentation ? 05:16 Quel est l’intérêt du cannabis thérapeutique [...]
Lire la suiteCSSS-N Commissions de la sécurité sociale et de la santé publique Secrétariat CH-3003 Berne www.parlament.ch sgk.csss@parl.admin.ch Vendredi, 03 mai 2019 15h50 Communiqué de presse Essais pilotes avec du cannabis: premier obstacle franchi La Commission de la sécurité sociale et de la santé publique du Conseil national est entrée en matière sur le projet prévoyant la création d’un article relatif aux projets pilotes dans la loi sur les stupéfiants. Elle souhaite permettre la réalisation d’études scientifiques sur la remise contrôlée de cannabis en vue d’une consommation récréative. Par 12 voix contre 9 et 2 abstentions, la Commission de la sécurité sociale et de la santé publique [...]
Lire la suiteSerotonergic psychedelics and personality: a systematic review of contemporary research José Carlos Bouso, Rafael G. dos Santos, Miguel Ángel Alcázar-Córcoles, Jaime E. C. Hallak Neuroscience and Biobehavioral Reviews, 2018 PII: S0149-7634(17)30301-9 DOI: https://doi.org/10.1016/j.neubiorev.2018.02.004 Highlights Serotonergic psychedelics act as agonists at cortical 5-HT2A receptors 5-HT2A receptors are expressed in fronto-temporo-parieto-occipital areas Some personality traits seem to be related to 5-HT2A receptor expression Acute and long-term use of psychedelics is associated with personality changes Personality changes induced by psychedelics may have therapeutic effects Abstract Serotonergic psychedelics act as agonists at cortical 5-HT2A receptors and seem to induce personality changes. We conducted a systematic review of studies assessing the effects [...]
Lire la suiteLong-term effects of ayahuasca in patients with recurrent depression : a 5-year qualitative follow-up Rafael G. dos Santos, Rafael Faria Sanches, Flávia de Lima Osório, Jaime E.C. Hallak Archive of Clinical Psychiatry, 2018, 45, 1, 22-4 DOI: 10.1590/0101-60830000000149 Abstract Background : Ayahuasca is a botanical hallucinogenic preparation traditionally used by indigenous populations of Northwestern Amazonian countries for ritual and therapeutic purposes. It is rich in β-carboline alkaloids and N,N-dimethyltryptamine (DMT). Preclinical, observational, and experimental studies suggest that ayahuasca and its alkaloids have anxiolytic and antidepressive effects. We recently reported in an open-label trial that ayahuasca administration was associated with significant decreases in depression symptoms for [...]
Lire la suiteFour Weekly Ayahuasca Sessions Lead to Increases in “Acceptance” Capacities : A Comparison Study With a Standard 8-Week Mindfulness Training Program Joaquim Soler, Matilde Elices, Elisabeth Dominguez-Clavé, Juan C. Pascual, Amanda Feilding, Mayte Navarro-Gil, Javier García-Campayo and Jordi Riba Frontiers in Pharmacology, 2018, 9, 224. doi: 10.3389/fphar.2018.00224 Background : The therapeutic effects of the Amazonian plant tea ayahuasca may relate to its ability to enhance mindfulness capacities. Ayahuasca induces a modified state of awareness through the combined action of its active principles: the psychedelic N,N-dimethyltryptamine (DMT) and a series of centrally acting b-carbolines, mainly harmine and tetrahydroharmine. To better understand the therapeutic potential of [...]
Lire la suiteCannabis For Cancer-Related Symptoms (CAFCARS) https://clinicaltrials.gov/ct2/show/NCT03948074?recrs=abdf&cond=cannabis&draw=2&rank=98 ClinicalTrials.gov Identifier: NCT03948074 Recruitment Status : Not yet recruiting First Posted : May 13, 2019 Last Update Posted : May 13, 2019 See Contacts and Locations Sponsor: Pippa Hawley Information provided by (Responsible Party): Pippa Hawley, British Columbia Cancer Agency Study Description Brief Summary: Clinical evidence is urgently needed to be able to advise patients on which cannabis-based products to take, or to avoid, in managing cancer-related symptoms. This trial was therefore designed to determine which cannabis extract combination (High THC-Low CBD, Low THC-High CBD, or Equal amounts of THC and CBD) is most effective at treating cancer related symptoms for each [...]
Lire la suite